PD-0332991 (Palbociclib) Hydrochloride from Selleck Chemicals

Product Specs
ItemPD-0332991 (Palbociclib) Hydrochloride
CompanySelleck Chemicals
Price $147.00Supplier Page View Company Product Page
Catalog NumberS1116
Quantity5mg
Purity99.61
TargetCDK
Storage2 years -80 in solvent
FormulaC24H29N7O2.HCl

Specifications/Features

Ki, IC, EC, or working concentration: IC50: 0.011 µmol/L for Cdk4
IC50: 0.016 µmol/L for Cdk6

Add to Compare List

Selleck Chemicals

14408 W Sylvanfield Drive

Houston, Texas TX 77014

United States

Phone: Toll Free: (877) 796-6397 (US and Canada only)
Tel: (832) 582-8158
Fax: (832) 582-8590

Email: sales@selleckchem.com

Company Profile

Website: www.selleckchem.com

(1) Potential effects of endogenous RNA/DNA hybrids on CRISPR/Cas9-mediated homology-directed repairMolecular Therapy Nucleic AcidsJune 16, 2026Francesco Puzzo, Batuhan Bayram, Claudia Macaubas, Angela Lin, Hagoon Jang, Feijie Zhang, Elizabeth Mellins, Mark A. Kayexperiments HEPA1-6/SpCas9 cells were treated with rapamycin (Selleck, S1039) or palbociclib (Selleck, S1116) for 24 h, fixed in 70% ethanol, stained with propidium iodide, and analyzed by flow cytometry (NovoCyte Penteon

(2) PIAS4 inhibition induces cell cycle arrest and exhibits a synergistic effect in combination with CDK4/6 inhibitor in breast cancer treatmentOncogeneMay 26, 2026Hui Chen, Xinyang Hu, Lifeng Feng, Xiaoqing Cheng, Liyuan Zhu, Fei Xu, Tao Zhu, Yongmei Gao, Jin Wang, Hongchuan Jin, et al.States). The following chemicals were used: N-ethylmaleimide (NEM; E3876, Sigma-Aldrich), palbociclib (S1116, Selleck), Subasumstat/TAK-981 (S8829, Selleck), 2-D08 (S8696, Selleck), and puromycin (S7417, Selleck).

(3) Patient-derived organoids guide personalized therapy for KRAS-mutant pancreatic cancer: synergistic MEK/mTOR inhibition and predictive chemotherapy responsesFront ImmunolMay 15, 2026Xiaorui Wang, Lijuan Liu, Feng Li, Yanyan Da, Fang Hu, Xin Qi, Yiwen Pan, Meng Jiang, Peng Hou, Jin Yang(S1209),Selleck,51-21-8 Paclitaxel,Selleck,S1150 Capecitabine,Selleck,S1156 Docetaxel,Selleck,S1148 AZD0156,Selleck,S8375 Olaparib,Selleck,S1060 AZD1390,Selleck,S8680 Trametinib,Selleck,S2673 GW5074,Selleck,S2872 RAF709,Selleck,S8690 TAK-632,Selleck,S7291 SB590885,Selleck,S2220 Palbociclib,Selleck,S1116 HLM006474,Selleck,S8963 Flavopiridol,Selleck,S1230 Ribociclib,Selleck,S7440 Gefitinib,Selleck,S1025 Erlotinib,Selleck,S7786 Afatinib,Selleck,S1011 Neratinib,Selleck,S2150 APR-246,Selleck,S7724 COTI-2,Selleck,S8580 Taselisib,Selleck,S7103 Alpelisib,Selleck,S2814 Buparlisib,Selleck,S2247 MK-2206,Selleck,S1078 Everolimus,Selleck,S1120 AZD8055,Selleck,S1555 Temsirolimus,Selleck,S1044

(4) Elevated Protein Tyrosine Phosphatase Kappa Expression Is Associated With Disease Progression and Poor Prognosis of Pancreatic CancerCancer Diagn PrognMay 1, 2026ZIQIAN FANG, XIANGYI LIU, XIUYUN TIAN, BILAL AL-SARIREH, CHUNYI HAO, WEN G. JIANG, LIN YEinhibitor BSJ-03-123 (Cat. No. 6921; TOCRIS, Bristol, UK), the dual CDK4/6 inhibitor Palbocicilib (Cat. No. S1116 Selleckchem, Houston, TX, USA), and the CDK4 inhibitor 3-ATA (Cat. No. sc-202414; Santa Cruz Biotechnology)

(5) The FAM53C/DYRK1A axis regulates the G1/S transition of the cell cycleElifeApril 30, 2026Taylar Hammond, Jong Bin Choi, Miles W Membreño, Janos Demeter, Roy Ng, Debadrita Bhattacharya, Thuyen N Nguyen, Griffin G Hartmann, Caterina I Colon, Carine Bossard, et al.Attardi. The following small molecule inhibitors were used in cells: palbociclib HCl (Selleckchem #S1116) and puromycin (Thermo Fisher #A1113803). For DYRK1A kinase inhibition, we used SM13797 from Biosplice

(6) THE FAM53C/DYRK1A axis regulates the G1/S transition of the cell cycleeLifeApril 30, 2026Taylar Hammond, Jong Bin Choi, Miles W Membreño, Janos Demeter, Roy Ng, Debadrita Bhattacharya, Thuyen N Nguyen, Griffin G Hartmann, Caterina I Colón, Carine Bossard, et al.Attardi. The following small molecule inhibitors were used in cells: palbociclib HCl (Selleckchem #S1116) and puromycin (Thermo Fisher #A1113803). For DYRK1A kinase inhibition, we used SM13797 from Biosplice

(7) Multi-omics analysis and functional validation reveal the oncogenic role of TRIP13Frontiers in ImmunologyApril 22, 2026Yuanqiao Zhao, Yongqi Zhao, Ruilin Liu, Jing Li, Yinhuai Wang1:2,000), and cleaved caspase 3 (#25128-1-AP Proteintech, Wuhan, China; 1:1,000). Palbociclib HCl (#S1116) was purchased from Selleck (Shanghai, China). The sources of all the other reagents are explicitly

(8) Targeting TPX2-dependent lineage plasticity by CDK4/6 inhibition reverses therapy resistance in neuroendocrine bladder carcinomaCell Reports MedicineApril 21, 2026Zehua Chen, Shengmeng Peng, Shi Fu, Shizhi Lin, Yiwen Su, Xinxin He, Yangjie Zhang, Junlin Lu, Sen Liu, Hengji Zhan, et al.Selleck, Cat#S1714], 10 μM Etoposide [Eto; Selleck, Cat#S1225], 5 μM Palbociclib [Pal, Selleck, Cat#S1116], or 10 μg/mL αPD-1 (Selleck, Cat#A3039) for a total of 72 h. At the end of treatment, SYTOX dye (KeyGEN,

(9) CSF1R inhibitors mitigate CDK4/6 inhibitor-induced immunosuppression to increase antitumor immunity in HR+/HER2− breast cancerOncogeneApril 15, 2026Siwei Li, Yajie Gong, Hui Li, Siyu Liu, Yanling Yin, Yuanyuan Yu, Yijun Chu, Jianxun Hou, Jialin Liu, Huaixi Zhang, et al.B and C [33]. Drug selection The cell and animal studies utilized several compounds: Palbociclib (S1116, Selleck), Pexidartinib (S7818, Selleck), INCB3344 (S8220, Selleck, USA), Stattic (HY-13818, MCE), Phorbol

(10) Uncovering cancer dependencies in peptide-interacting protein pocketsbioRxivMarch 25, 2026Mihkel Örd, Liz Kogan, Devin Bradburn, Michelle Leiser, Mardo Kõivomägi, Norman E. Davey, Pau Creixellin DMSO. Squarunkin A (HY-127002, Cambridge Bioscience) was dissolved at 5 mM in DMSO. Palbociclib (S1116, Selleck) was dissolved at 10 mM in DMSO. Atirmociclib (PF-07220060, M45136, Clinisciences Limited)

(11) Exploring the mechanism of action of abemaciclib in breast cancer through circulating chromatin fragmentsCommunications MedicineMarch 18, 2026Mamoru Takada, Sakuntha Gunarathna, Regina Nguyen, Muhan Yu, Paige Bonnet, Hideyuki Yamada, Takeshi Nagashima, Hiroshi Fujimoto, Junta Sakakibara, Hiroto Yamamoto, et al.inhibitor). DMSO (0.1%) was used for control. Abemaciclib was purchased as a 5 mg powder (Selleckchem, S1116) and dissolved in 100% DMSO to prepare stock solutions. GSK126 (GSK2816126A), a selective EZH2 methyltransferase

(12) CDK4/6 inhibition mitigates chemotherapy-induced expansion of TP53-mutant clonal hematopoiesisNat GenetMarch 11, 2026Irenaeus C. C. Chan, Pu Zhang, Xiangyu Pan, Cynthia Castro, Nina Fox, Alexander M. Lewis, Kenyon Weis, Adriana Cuibus, Steven Tittley, Giulia Petrone, et al.8-week-old female B6.SJL-Ptprca Pepcb/BoyJ mice were given oral gavage of palbociclib (100 mg kg−1; S1116, Selleckchem), and the other half vehicle (0.9% NaCl; daily). A single intraperitoneal injection of

(13) Design of combination therapeutics from protein response to drugs in ovarian cancer cellsbioRxivFebruary 27, 2026Alexandra Franz, Ciyue Shen, Fabian Coscia, Kenneth Munroe, Lea Charaoui, Anil Korkut, Matthias Mann, Augustin Luna, Chris Sander#S1120), Ivosidenib (Selleckchem, #S8206), Erlotinib (Selleckchem, #S7786), Palbociclib (Selleckchem, #S1116), Bosutinib (Selleckchem, #S1014), Idelalisib (Selleckchem, #S2226), and Auranofin (Selleckchem, #S4307). Cells

(14) Mitochondrial bioenergetics-SASP crosstalk determines senolytic efficacy in therapy-induced senescenceCell Death DiscoveryFebruary 19, 2026Àngela Llop-Hernández, Sara Verdura, Júlia López, Begoña Martin-Castillo, Javier A. Menendez, Elisabet Cuyàsintermittently tested thereafter. Drugs and reagents Doxorubicin (#S1208), PD-0332991/palbociclib (#S1116), ABT-263/navitoclax (#S1001), A1331852 (Cat. #S7801), etomoxir (Cat. #S8244), and an antibody against

(15) Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational StatusInternational Journal of Molecular SciencesFebruary 12, 2026Madison Bittner, Marta Llaurado Fernandez, Joshua Hoenisch, Yuen Yee Leung, Hannah Kim, Nelson K. Y. Wong, Kathleen I. Pishas, Dane Cheasley, Karla J. Cowley, Kaylene J. Simpson, et al.selection: TRA (GSK1120212; Cedarlane; Sellekchem, Cat. No. S2673) or PLB (Cedarlane; Selleckchem, Cat. No. S1116). As in the protocol outlined by Coley et al., increasing amounts of drug (TRA or PLB) were used until

(16) Targeting PFKFB3 to enhance CDK4/6 inhibitor response in ER+ breast cancerResearch SquareFebruary 10, 2026Sucheta Telang, Brian F Clem, Ariamna A Herrera Miret, Leanne Price, Susan M Dougherty, Anna Schmitz, Xinmin Yin, Xipeng Ma, Xiang Zhang, Jason Chesney, et al.using cells within 15 passages after reconstitution from frozen stocks. Drug Treatments Palbociclib (S1116; Selleckchem), ribociclib (S7440; Selleckchem), and PFK-158 (HY-12203; MedChem Express) were used in

(17) CRISPR screen of human pancreatic cancer xenografts identifies a KLF5 proliferation vulnerability through epigenetic modifiers NCAPD2 and MTHFD1Molecular CancerFebruary 10, 2026Masahiro Maeda, Kenna Sherman, Weiqiang Zhou, Jiaqi Cheng, Yuta Nihongaki, Adrian Idrizi, Rakel Tryggvadottir, Oscar Camacho, Xingbo Shang, Jimin Min, et al.calculated. Reagents and antibodies JNJ-7706621 (S1249), Flavopiridol (L86-8275, S1230), Palbociclib (PD-0332991, S1116), Baricitinib (INCB028050, S2851), Cerdulatinib (PRT062070, S3566) and Erlotinib (S1123) were purchased

(18) Transient proliferation by reversible YAP and mitogen control of the cyclin D1/p27 ratioCommunications BiologyJanuary 29, 2026Katherine R. Ferrick, Samsara W. Upadhya, Yilin Fan, Nalin Ratnayeke, Mary N. Teruel, Tobias Meyer(Selleck Chemicals Cat#S1036, CAS#391210-10-9, MEKi), 1 μM palbociclib (PD-0332991, Selleck Chemicals cat#S1116, CAS#827022-32-2, CDK4/6i), 0.5 µg/mL doxycycline hyclate (Sigma-Aldrich cat#D9891, CAS#24390-14-5,

(19) PAF15–PCNA exhaustion governs the strand-specific control of DNA replicationNatureJanuary 28, 2026Gita Chhetri, Sugith Babu Badugu, Narcis-Adrian Petriman, Mikkel Bo Petersen, Aylin Seren Güller, Nora Fajri, Manon Coulée, Ganesha Pandian Pitchai, Jan Novotný, Frederik Tibert Larsen, et al.(MK-1775) (WEE1 inhibitor; Selleckchem, s1525), palbociclib (PD-0332991) (CDK4/6 inhibitor; Selleckchem, S1116), MG132 (proteasome inhibitor; Selleckchem, s2619), bortezomib (proteasome inhibitor; Selleckchem, S1013),

(20) Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancereLifeDecember 29, 2025Jessica Armand, Sungsoo Kim, Kibum Kim, Eugene Son, Minah Kim, Kevin Kalinsky, Hee Won Yangmycoplasma contamination. Drugs and chemicals For in vitro experiments, palbociclib (Selleck Chemicals, S1116), INX-315 (MedChemExpress, HY-162001), and fulvestrant (Selleck Chemicals, S1191) were dissolved in

Be the First to Write a Review!